DDrare: Database of Drug Development for Rare Diseases

15. 封入体筋炎
［臨床試験数：39，薬物数：32（DrugBank：11），標的遺伝子数：11，標的パスウェイ数：119］

Searched query = "Inclusion body myositis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ABC008; ARIMOCLOMOL; Alemtuzumab; Alemtuzumab (Campath); Anakinra; Arimoclomol; Arimoclomol citrate; BOTULINUM TOXIN TYPE A; BRX-345; BYM338; BYM338 (Bimagrumab); BYM338/bimagrumab; Bimagrumab; Botulinum toxin type A; Care as usual; Etanercept; FLEBOGAMMA 5%; Gamma Globulin; Immunoglobulins, normal human, for intravascular adm.; Natalizumab; Null; Other: Blood-flow restricted training; Phenylbutyrate; Phenylbutyrate Oral Tablet; Pioglitazone; RAAV1.CMV.huFollistatin344; REGN2477+REGN1033; Rapamycin; SIVASTIN; Simvastatin; Sivastin; Xeomin

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02483845 (ClinicalTrials.gov)	May 2013	31/5/2013	Natalizumab in Inclusion Body Myositis (IBM)	Pilot Study of Natalizumab in the Treatment of Patients With Inclusion Body Myositis	Inclusion Body Myositis (IBM)	Drug: Natalizumab	Phoenix Neurological Associates, LTD	NULL	Active, not recruiting	21 Years	85 Years	All	6	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02483845
(ClinicalTrials.gov)

May 2013

31/5/2013

Natalizumab in Inclusion Body Myositis (IBM)

Pilot Study of Natalizumab in the Treatment of Patients With Inclusion Body Myositis

Inclusion Body Myositis (IBM)

Drug: Natalizumab

Phoenix Neurological Associates, LTD

NULL

Active, not recruiting

21 Years

85 Years

All

Phase 1

United States